A quantitative upgrade and chart patterns may do the trick.
'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.
Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.
Investors shouldn't ruffle their feathers. At least, not yet.